Page 1

Interim report 1 January – 30 June 2021 Q2 Q - LINEA COMMERCIALISATION OF ASTar STARTED Second quarter : 1 April – 30 June 2021 Net sales amounted to SEK 4.3 million ( 0.1 ) . The operating result totalled SEK -68.2 million ( -58.6 ) . • The result for the period amounted to SEK -68.0 million ( -57.4 ) . • Earnings per share before and after dilution amounted to SEK -2.47 ( -2.37 ) . • Cash flow from operating activities totalled SEK -45.0 million ( -54.8 ) . Period : 1 January - 30 June 2021 . Net sales amounted to SEK 4.3 million ( 0.2 ) . . The operating result totalled SEK -131.9 million ( -114.5 ) . . The result for the period amounted to SEK -131.1 million ( -113.4 ) . • Earnings per share before and after dilution amounted to SEK -4.81 ( -4.81 ) . • Cash flow from operating activities totalled SEK -101.1 million ( -113.9 ) . At 30 June 2021 , cash and cash equivalents totalled SEK 48.1 million ( 10.1 ) . Short - term investments in fixed- income funds amounted to SEK 221.4 million ( 165.7 ) , short - term components of listed corporate bonds to SEK 57.1 million ( 131.0 ) and long - term investments in listed corporate bonds to SEK 184.2 million ( 24.4 ) . Significant events in the second quarter of 2021 The Company achieved CE - IVD approval for ASTar and carried out the first sales of ASTar instruments and consumables to Thermo Fisher Scientific . • Q - linea initiated a US regulatory study for ASTar . . Q - linea carried out a directed issue of 2.2 million shares in June 2021 , raising gross proceeds of SEK 301.4 million . The Annual General Meeting was held on 25 May . Refer to " Other information " for information about the resolutions passed at the Annual General Meeting . after the end of the period • No significant events took place after the end of the period . Q - LINEA | INTERIM REPORT | Q1 2021 1